Columbia, MD—November 12, 2025—Precision Antibody, a leader in custom monoclonal antibody development, is pleased to announce its participation in the 20th Drug Discovery Strategic Summit (DDSS Europe), taking place November 19–20, 2025, in Amsterdam, Netherlands.

The DDSS Europe brings together industry leaders, researchers, and innovators shaping the future of drug discovery and development. Precision Antibody will join this global scientific community to share insights on its high-quality, application-ready monoclonal antibody development solutions designed to accelerate biomarker research, diagnostic development, and therapeutic innovation.

As a trusted partner to the biopharmaceutical and life sciences community, Precision Antibody has earned recognition for its ability to deliver antibodies that work “right the first time.” The company’s expertise in biomarker antibody development and custom monoclonal antibody production continues to support cutting-edge research efforts across oncology, immunology, and precision medicine.

“Participating in DDSS Europe is an exciting opportunity to engage with leading scientists and innovators in the global drug discovery community,” said Dr. Serrero. “Our mission has always been to enable faster, more reliable antibody development—empowering researchers to translate discovery into therapeutic success.”

With a strong track record of success in developing high-quality biomarker antibodies, Precision Antibody proudly contributes to the National Cancer Institute’s Clinical Proteomic Technologies for Cancer (CPTC) program through Leidos, helping establish gold-standard monoclonal antibodies for cancer biomarker research.

Attendees of DDSS Europe 2025 are invited to connect with the Precision Antibody team in Amsterdam to learn more about how the company’s custom antibody development platform can support their drug discovery and biomarker validation needs.

About Precision Antibody
Founded in 2000, Precision Antibody is a U.S.-based biotechnology company specializing in the rapid development of custom monoclonal antibodies. Known for delivering antibodies that work “right the first time,” the company supports pharmaceutical, biotech, academic, and government researchers worldwide. With a proven track record in biomarker antibody development and contributions to the NCI’s Clinical Proteomic Technologies for Cancer (CPTC) program, Precision Antibody is recognized for setting benchmarks in antibody quality and reliability. In 2025, the company was honored as the Best Monoclonal Antibody Development Company, reinforcing its leadership and commitment to advancing diagnostics, therapeutics, and translational research through high-performance, royalty-free antibodies.